AEL completes Neovastat Phase III enrollment

Aeterna (TSE:AEL; AELA) completed enrollment in Europe and North America for a 280-patient Phase III trial of its Neovastat, an oral blocker of angiogenesis and inducer of apoptosis, to treat renal ce...